Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV) - PubMed
5 hours ago
- #Urothelial Carcinoma
- #Immunotherapy
- #Real-world Data
- Study evaluates real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in advanced urothelial carcinoma with squamous differentiation (UCSD).
- Retrospective, international, multicenter analysis (ARON-2EV) included 1918 patients (1696 pure UC, 222 UCSD) across 79 centers in 21 countries.
- Primary endpoints: overall survival (OS) and time on treatment (ToT). Secondary objectives included clinical factors and UCSD impact on therapy response.
- Median OS was shorter in UCSD vs. pure UC across all cohorts (avelumab: 13.0 vs. 26.8 months; pembrolizumab: 10.2 vs. 18.5 months; EV: 7.6 vs. 13.1 months).
- ToT was shorter in UCSD for avelumab (3.5 vs. 5.6 months) and EV (7.6 vs. 13.6 months), but not pembrolizumab (3.7 vs. 4.7 months).
- UCSD histology negatively correlated with therapy response in pembrolizumab and EV cohorts, but not avelumab.
- Conclusions: UCSD has poorer prognosis and treatment response compared to pure UC, warranting dedicated prospective studies.